Expanding HL7 FHIR to support post-marketing research and surveillance within multi-source, chronic disease registries
Expanding HL7 FHIR to support post-marketing research and surveillance within multi-source, chronic disease registries
批准号:
9757693
负责人:
MARC DAVID NATTER
金额:
$10.0万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-01 至 2022-08-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Improvements in the scalability and timeliness of traditional clinical research trial models increasingly rely upon
incorporation of added sources of `Real World Data' (RWD) – data from electronic health record systems
(EHRs), observational studies and disease registries, and patient and/or caregiver report. Similarly,
observational, post-marketing drug safety surveillance efforts also remain limited in capability and cost-
effectiveness until these other important, added sources of RWD are able to be incorporated in a facile,
efficient, and timely fashion. Conventional data interchange standards such as HL7 v3 and Clinical Data
Interchange Standards Consortium (CDISC) standards, e.g. Operational Data Model (ODM-XML), Define-XML,
Data-XML, are not well-adopted, often limited in suitability, and not focused on modern API-based interchange
of RWD. The overall goal of this proposed project is the development and demonstration of new FHIR
extensions, profiles, resources, and implementations that support FDA 21 CFR 11-compliant workflows for
disease registry-based information exchange, thereby providing important advantages over current, non-FHIR-
based approaches for conducting such studies. We leverage the expertise and extensive experience of the
participating investigators and institutions, who are collecting and using RWD for Phase IV safety surveillance
activities, and who are already utilizing FHIR for warehousing of this data. Specifically, we target two high-
value, readily achievable, and broadly relevant areas for application of FHIR data interchange standards to this
domain: (1) Incorporation of patient-reported outcomes (PRO) data into 21 CFR 11-compliant workflows using
FHIR, and (2) Enablement of a standardized approach within FHIR to query and deliver reproducible data sets
supporting 21 CFR11-compliant analyses suitable for post-marketing safety surveillance. As part of this
project, we will submit these improvements to HL7 for incorporation into FHIR, make our implementations
publicly available, and also produce a white paper summarizing the work accomplished, potential paths
forward for using the products, and best practices or concerns that should be addressed in subsequent work.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Foundational Collaborations and Capabilities to Advance Exposome Research in Childhood-onset Rheumatic Diseases and other Pediatric Autoimmune Conditions
-
批准号:10868992
-
项目类别:
-
资助金额:$48.68万
-
财政年份:2023
-
负责人:MARC DAVID NATTER
-
依托单位:
海外基金